Gene therapy for dopamine replacement in Parkinson's disease.
Björklund, Anders LU
; Björklund, Tomas
LU
and Kirik, Deniz
LU
(2009)
In Science Translational Medicine
1(2).
p.2-2
- Abstract
- The introduction of L-dopa (L-3,4-dihydroxyphenylalanine) therapy 40 years ago was a revolution in the treatment of patients with Parkinson s disease (PD). With time, however, the shortcomings of oral L-dopa medication became apparent, in particular the appearance of troublesome side effects, expressed as involuntary movements (dyskinesias) that developed over time in many patients. A gene therapy approach, aimed at restoring dopamine synthesis in the affected brain by viral vector delivery of genes that encode the dopamine-synthesizing enzymes, may offer a solution to this problem. Now, a team of French and UK researchers reports promising results in a nonhuman primate model of PD, paving the way for clinical trials of this... (More)
- The introduction of L-dopa (L-3,4-dihydroxyphenylalanine) therapy 40 years ago was a revolution in the treatment of patients with Parkinson s disease (PD). With time, however, the shortcomings of oral L-dopa medication became apparent, in particular the appearance of troublesome side effects, expressed as involuntary movements (dyskinesias) that developed over time in many patients. A gene therapy approach, aimed at restoring dopamine synthesis in the affected brain by viral vector delivery of genes that encode the dopamine-synthesizing enzymes, may offer a solution to this problem. Now, a team of French and UK researchers reports promising results in a nonhuman primate model of PD, paving the way for clinical trials of this enzyme-replacement approach. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/1595589
- author
- Björklund, Anders
LU
; Björklund, Tomas
LU
and Kirik, Deniz
LU
- organization
- publishing date
- 2009
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Science Translational Medicine
- volume
- 1
- issue
- 2
- pages
- 2 - 2
- publisher
- American Association for the Advancement of Science (AAAS)
- external identifiers
-
- wos:000277147600002
- pmid:20368161
- scopus:76949092638
- pmid:20368161
- ISSN
- 1946-6242
- DOI
- 10.1126/scitranslmed.3000350
- language
- English
- LU publication?
- yes
- id
- 56c94388-dc90-4bab-944b-60887490136c (old id 1595589)
- alternative location
- http://www.ncbi.nlm.nih.gov/pubmed/20368161?dopt=Abstract
- date added to LUP
- 2016-04-04 07:26:46
- date last changed
- 2022-02-13 05:00:36
@article{56c94388-dc90-4bab-944b-60887490136c,
abstract = {{The introduction of L-dopa (L-3,4-dihydroxyphenylalanine) therapy 40 years ago was a revolution in the treatment of patients with Parkinson s disease (PD). With time, however, the shortcomings of oral L-dopa medication became apparent, in particular the appearance of troublesome side effects, expressed as involuntary movements (dyskinesias) that developed over time in many patients. A gene therapy approach, aimed at restoring dopamine synthesis in the affected brain by viral vector delivery of genes that encode the dopamine-synthesizing enzymes, may offer a solution to this problem. Now, a team of French and UK researchers reports promising results in a nonhuman primate model of PD, paving the way for clinical trials of this enzyme-replacement approach.}},
author = {{Björklund, Anders and Björklund, Tomas and Kirik, Deniz}},
issn = {{1946-6242}},
language = {{eng}},
number = {{2}},
pages = {{2--2}},
publisher = {{American Association for the Advancement of Science (AAAS)}},
series = {{Science Translational Medicine}},
title = {{Gene therapy for dopamine replacement in Parkinson's disease.}},
url = {{http://dx.doi.org/10.1126/scitranslmed.3000350}},
doi = {{10.1126/scitranslmed.3000350}},
volume = {{1}},
year = {{2009}},
}